[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100471368":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":14,"centralContacts":19,"locations":29,"responsibleParty":58,"collaborators":7,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":7,"eligibilityCriteria":66,"healthyVolunteers":62,"sex":67,"minAge":68,"maxAge":7,"enrollmentInfo":69,"targetDuration":7,"studyType":72,"phases":7,"briefSummary":73,"conditions":74,"keywords":7,"overallStatus":31,"whyStopped":7,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Northside Hospital, Inc.","OTHER",null,[9],{"type":6,"name":10,"description":11,"armGroupLabels":7,"otherNames":12},"Fludarabine","Reduced-intensity fludarabine with intermediate-dose TBI",[13],"Total Body Irradiation",[15],{"name":16,"affiliation":17,"role":18},"Scott Solomon, MD","BMTGA","PRINCIPAL_INVESTIGATOR",[20,25],{"name":21,"role":22,"phone":23,"phoneExt":7,"email":24},"Stacey Brown","CONTACT","404-480-7965","stacey.brown@northside.com",{"name":26,"role":22,"phone":27,"phoneExt":7,"email":28},"Caitlin Guzowski","404-851-8523","caitlin.guzowski@northside.com",[30],{"facility":26,"status":31,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"RECRUITING","Atlanta","Georgia","30342","United States","US",{"type":38,"coordinates":39},"Point",[40,41],-84.38798,33.749,{"lat":41,"lon":40},[44,46,49,51,53,54,56],{"name":45,"role":22,"phone":27,"phoneExt":7,"email":28},"Caitlin Guzowski, MBA, MHA",{"name":47,"role":48,"phone":7,"phoneExt":7,"email":7},"H. Kent Holland, MD","SUB_INVESTIGATOR",{"name":50,"role":48,"phone":7,"phoneExt":7,"email":7},"Asad Bashey, MD",{"name":52,"role":48,"phone":7,"phoneExt":7,"email":7},"Lawrence E Morris, MD",{"name":16,"role":48,"phone":7,"phoneExt":7,"email":7},{"name":55,"role":18,"phone":7,"phoneExt":7,"email":7},"Melhem Solh, MD",{"name":57,"role":48,"phone":7,"phoneExt":7,"email":7},"Lizamarie Bachier-Rodriguez, MD",{"type":59,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100471368","reduced-intensity-fludarabine-and-tbi-prior-to-haplo-identical-transplantation-100471368",false,"NCT05417971","Reduced Intensity Fludarabine and TBI Prior to Haplo-Identical Transplantation","A Phase II Trial of Reduced Intensity Fludarabine and Total Body Irradiation-Based Conditioning Prior to Haplo-Identical Transplantation for Patients With Hematologic Malignancies","Inclusion Criteria:\n\n* Availability of 3\u002F6 - 5\u002F6 matched related donor with a negative HLA-cross match in the host vs. graft direction willing to donate peripheral blood stem cells\n* KPS \\>\u002F= 70%\n* Hematologic malignancy requiring allogeneic transplantation, with a predicted high risk of relapse following non-myeloablative, low intensity conditioning.\n\nExclusion Criteria:\n\n* Poor cardiac function (LVEF \\\u003C45%)\n* Poor pulmonary function (FEV, FVC, DLCO \\\u003C60%)\n* Poor liver function (bilirubin \\>\u002F= 2.5mg\u002FdL; AST or ALT \\>3xULN)\n* Poor renal function (creatinine clearance \\\u003C40mL\u002Fmin)\n* HIV-positive; active HepB or HepC\n* Uncontrolled infection\n* Pregnant female or not able to practice adequate contraception\n* Debilitating medical or psychiatric illness which would preclude their giving informed consent","ALL","18 Years",{"count":70,"type":71},20,"ESTIMATED","OBSERVATIONAL","This trial will evaluate the safety and efficacy of RIC HIDT transplant protocol following fludarabine and intermediate-dose TBI 800 cGy utilizing PBSC as the stem cell source.",[75],"Hematologic Malignancy","2026-04-15",{"date":78,"type":79},"2026-04-16","ACTUAL",{"date":81,"type":79},"2022-08-29",{"date":83,"type":71},"2026-12-31",{"name":5,"class":6},1]